Vertex Pharmaceuticals Inc. reported results of Phase 3 clinical trials of ivacaftor (VX-770) in combination with lumacaftor (VX-809) for CF patients who are homozygous for F508del-CFTR. Here, CFTR is linked to cystic fibrosis.